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Cardiovascular diseaseMatrix metalloproteinases (MMPs) are a large family of zinc-endopeptidases which play important roles in
multiple physiological and pathological processes. These enzymes are widely distributed in all kingdoms of
life and have likely evolved from a single-domain protein which underwent successive rounds of duplication,
gene fusion and exon shufﬂing events to generate the multidomain architecture and functional diversity
currently exhibited by MMPs. Proper regulation of these enzymes is required to prevent their unwanted
activity in a variety of disorders, including cancer, arthritis and cardiovascular diseases. Multiple hormones,
cytokines and growth factors are able to induce MMP expression, although the tissue speciﬁcity of the
diverse family members is mainly achieved by the combination of different transcriptional control
mechanisms. The integration of multiple signaling pathways, coupled with the cooperation between several
cis-regulatory elements found at the MMP promoters facilitates the strict spatiotemporal control of MMP
transcriptional activity. Additionally, epigenetic mechanisms, such as DNAmethylation or histone acetylation,
may also contribute to MMP regulation. Likewise, post-transcriptional regulatory processes including mRNA
stability, protein translational efﬁciency, and microRNA-based mechanisms have been recently described as
modulators of MMP gene expression. Parallel studies have led to the identiﬁcation of MMP polymorphisms
and mutations causally implicated in the development of different genetic diseases. These genomic analyses
have been further extended through the generation of animal models of gain- or loss-of-function for MMPs
which have allowed the identiﬁcation of novel functions for these enzymes and the establishment of causal
relationships between MMP dysregulation and development of different human diseases. Further genomic
studies of MMPs, including functional analysis of gene regulation and generation of novel animal models will
help to answer the multiple questions still open in relation to a family of enzymes which strongly inﬂuence
multiple events in life and disease.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Matrixmetalloproteinases (MMPs) comprise a large family of zinc-
dependent endoproteinases, collectively capable of degrading all
extracellularmatrix (ECM) components. MMPs (also calledmatrixins)
are found in all kingdoms of life and belong to the metzincin
superfamily of metalloproteinases, which is characterized by the
presence of a catalytic zinc atom in their active center followed by a
conserved methionine residue [1]. To date, at least 25 different
vertebrate MMPs have been identiﬁed, 24 of which are present in
humans, including two recently duplicated genes encoding MMP-23
[2].
The proteolytic activities of MMPs inﬂuence essential cellular
processes like cell proliferation, migration and adhesion, as well as
many fundamental physiological events involving tissue remodeling,34 985 103564.
ll rights reserved.such as angiogenesis, bone development, wound healing, and uterine
and mammary involution [3,4]. However, the increasing relevance of
this family of proteases mainly derives from the high number of
pathological conditions where these enzymes have been implicated
[5,6]. Thus, upregulation of MMPs has been reported in cancer,
vascular diseases and many different types of inﬂammatory pathol-
ogies, supporting the need of a precise spatiotemporal regulation of
MMPs to maintain a proper homeostasis of the extracellular and
pericellular environment. MMP expression and activity can be
regulated at different levels including gene transcription, proenzyme
activation and endogenous inhibition, which act in a coordinated
manner to conﬁne the diverse MMP proteolytic activities to those
conditions and locations where they are necessary. Unfortunately,
these restrictive regulatory mechanisms are frequently lost in multi-
ple pathological conditions, as assessed from studies based on the use
of gain- or loss-of-function of MMPs in animal models [7]. These
models have also provided important clues about the functional
relevance of MMPs in a variety of physiological processes taking place
in all organismswith ability to produce these proteases. In this review,
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MMPs, we will focus on genomic characteristics of this family of
proteolytic enzymes, paying special attention to gene organization
and evolution. Likewise, we will discuss different levels of MMP gene
regulation with particular emphasis on the mechanisms responsible
for their transcriptional control and on the presentation of data on
epigenetic and post-transcriptional regulation of these protease
genes. Finally, we will present the most recent information about
MMP polymorphisms and mutations associated with human pathol-
ogies, as well as those mouse models generated by genetic manipula-
tion which have shed light on the functional relevance of these
enzymes in life and disease.
2. Matrix metalloproteinases: Classiﬁcation and biochemical
properties
MMPs or matrixins are synthesized as zymogens with a signal
peptide which leads them to the secretory pathway. Then, these en-
zymes can be secreted from the cell or anchored to the plasma
membrane, thereby conﬁning their catalytic activity to the extra-
cellular space or to the cell surface, respectively. Interestingly, recent
studies have reported that several MMP family members, such as
MMP-1 [8], MMP-2 [9], MMP-11 [10] and MMP-13 [11], can be found
as intracellular proteins, although their functions at this subcellular
location are still unclear. The archetypal MMPs consist of a propeptide
(∼80 amino acids) with a cysteine-switch motif, a catalytic metallo-
proteinase domain (∼170 amino acids), a linker peptide of variable
length and a hemopexin domain (∼200 amino acids). Nevertheless,
the family of MMPs has evolved into different groups by remo-
ving some domains or by incorporating others which are absent in
the previously described basic core (Fig. 1). Thus, based on their
domain organization, MMPs can be classiﬁed in four different groups:
archetypal MMPs, matrilysins, gelatinases and furin-activatable
MMPs.Fig. 1. The mammalian family of matrix metalloproteinases. Structu2.1. Archetypal MMPs
Within this category, and according to their substrate speciﬁcities,
we can establish three different subgroups: collagenases, stromelysins
and other archetypal MMPs.
2.1.1. Collagenases
This subgroup is composed of three enzymes, MMP-1, MMP-8 and
MMP-13 (also known as collagenases-1, 2, and 3, respectively) whose
name reﬂects their ability to cleave the collagen triple helix into
characteristic 3/4 and 1/4 fragments. In addition, collagenases are
also able to proteolytically process other ECM proteins, as well as a
number of bioactive molecules such as interleukin-8 (IL-8) [12], pro-
tumor necrosis factor (TNF)-α [13], protease-activated receptor-1
[14], and several insulin-like growth factor binding proteins (IGFBPs)
[15]. Removal of the hemopexin domain turns these MMPs into
enzymes unable to degrade native collagen, suggesting that the
cooperation between the catalytic and hemopexin domains is
essential to carry out their collagenolytic activity [16]. A fourth type
of collagenase (MMP-18) has been identiﬁed in Xenopus [17], but it
does not have any known orthologue in mammals.
2.1.2. Stromelysins
Stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10) show the
same structural design as collagenases and can degrade many
different ECM components, but they are not able to cleave native
collagen. In addition, stromelysin-1 also processes several bioactive
substrates including stromal-cell derived factor-1, E-cadherin, and
pro-interleukin-1 beta (IL-1β) [15]. Likewise, stromelysins participate
in proMMP activation through their ability to remove the propeptide
domain of the three procollagenases [18] and proMMP-9 [19],
generating the fully active form of these enzymes. Stromelysins are
expressed by both ﬁbroblast and epithelial cells, and are secreted to
the extracellular space where they play important roles in biologicalral classiﬁcation of MMPs based on their domain arrangement.
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wound healing [3]. There is another MMP called stromelysin-3
(MMP-11) which shares some structural characteristics with strome-
lysins but due to the presence of additional features, it is classiﬁed into
the category of furin-activatable MMPs.
2.1.3. Other archetypal MMPs
There are four matrixins (MMP-12, -19, -20, -27) which cannot be
classiﬁed in the previous subgroups because of their divergence in
sequence and substrate speciﬁcity. MMP-12 or metalloelastase is the
most potent elastolytic enzyme of the family although, as otherMMPs,
it can also degrade many other ECM proteins, including aggrecan,
ﬁbronectin, laminin, and type IV collagen [15]. MMP-12 is mainly
expressed by macrophages [20] but it is also produced by hyper-
trophic chondrocytes and osteoclasts [21]. MMP-19 was ﬁrst isolated
from human cDNA liver libraries [22] and, afterwards, it was detected
in the inﬂamed synovium from patients with rheumatoid arthritis
[23]. This MMP is expressed in a wide variety of human tissues and
exhibits a potent degradative activity against components of base-
ment membranes, such as type IV collagen or tenascin, as well as
gelatin and aggrecan [24]. MMP-20, also named enamelysin because
of its ﬁrst isolation from a porcine enamel organ, is secreted by
ameloblasts and odontoblasts of the dental papila, which are involved
in tooth enamel formation [25,26]. MMP-27 was ﬁrst cloned from a
chicken embryo ﬁbroblasts cDNA library [27]. It has been reported
that this chicken enzyme is able to degrade gelatin and casein, but
little information is available about the activity of its human
orthologue, which is highly expressed in B-lymphocytes [28].
2.2. Matrilysins
MMP-7 and MMP-26, also known as matrilysins-1 and -2, are
expressed under normal and pathological conditions and have been
implicated in the progression of several types of human cancers. Both
proteases exhibit the simplest domain arrangement of all MMPs since
they lack the carboxy-terminal hemopexin domain [29]. Matrilysins
play important roles in the degradation of ECM proteins like type IV
collagen, laminin and entactin [15], as well as in the processing of non-
ECM proteins. Thus, MMP-7 catalyzes the ectodomain shedding of
several cell surface molecules like Fas ligand [30], E-cadherin [31] and
syndecan-1 [32], whereas MMP-26 has been reported to be an
activator of proMMP-9 under pathological conditions [33]. In addition,
matrilysins have been associated with the remodeling of the post-
partum uterus and with embryo implantation [34].
2.3. Gelatinases
MMP-2 (gelatinase-A) and MMP-9 (gelatinase-B) are constitu-
tively expressed by many cell types including ﬁbroblasts, keratino-
cytes, endothelial cells, chondrocytes and monocytes in the case of
MMP-2, and alveolar macrophages, polymorphonuclear leukocytes
and osteoclasts in the case of MMP-9. These MMPs have an additional
ﬁbronectin domain located inside the catalytic domain, which allows
the binding and processing of denatured collagen or gelatin [1],
suggesting that these enzymes also play a key role in the remodeling
of collagenous ECM. Thus, gelatinases degrade a broad spectrum of
ECM molecules such as collagen types I, IV, V, VII, X, IX, elastin,
ﬁbronectin, aggrecan, vitronectin, laminin [15], but also many non-
ECM molecules including pro-TNF-α [13], transforming growth factor
(TGF)-β [35], pro-IL-1β, pro-IL-8 and monocyte chemoattractant
protein (MCP)-3 [36]. Likewise, these enzymes are able to release or
generate several factors with pro- or anti-angiogenic properties [37].
Both gelatinases have been associated with multiple pathologies,
including cancer, bone diseases, inﬂammatory disorders and vascular
alterations such as atherosclerosis, aortic aneurysm and myocardial
infarction [5].2.4. Furin-activatable MMPs
All MMPs belonging to this category contain a furin recognition
motif inserted between the propeptide and the catalytic domain. This
sequence is recognized and cleaved by convertase proteases, provid-
ing the basis for furin-dependent activation of latent enzymes prior to
secretion. These furin-activatable MMPs include three secretedMMPs,
six membrane-type-MMPs and two unusual type II transmembrane
MMPs.
2.4.1. Secreted MMPs (MMP-11, -21, and -28)
Unlike the other secreted MMPs, these three furin-activatable
enzymes are processed intracellularly by furin-like proteases and
secreted as active forms. MMP-11, also known as stromelysin-3, is
expressed during embryogenesis, tissue involution and wound healing,
and has been proposed to play an important role in cancer [38]. Recent
studies have reported that MMP-11 is induced in adipose tissue by
cancer cells and contributes to tumor progression through the
degradation of collagen VI, suggesting a molecular link between obesity
and cancer [39]. MMP-21 is the human orthologue of Xenopus XMMP
and it has been detected during embryo development in several organs
such as kidney, intestine and skin, aswell as in various epithelial cancers
[40]. MMP-28, also known as epilysin, is expressed in several adult
tissues such as testis, lung, heart, colon, intestine, brain and epidermis
[41]. MMP-28 is also produced by several carcinomas but its functional
role in transformation events has not been clearly deﬁned. In addition,
recent data have reported that epilysinmay be an importantmediator in
certain diseases of the central nervous system, such asmultiple sclerosis,
where it may participate in demyelinating processes [42].
2.4.2. Membrane-type MMPs (MMP-14, -15, -16, -17, -24, and -25)
These MMPs incorporate membrane-anchoring domains that
locate them at the cell surface. This feature makes these enzymes as
optimal pericellular proteolytic machines, able to control the local
environment that surrounds normal and tumoral cells. On the basis of
their type of attachment to the plasma membrane, MT-MMPs can be
classiﬁed into two groups: type I transmembrane MT-MMPs and
glycosylphosphatidylinositol (GPI) MT-MMPs [43]. The ﬁrst group
comprises MT1-, MT2-, MT3-, and MT5-MMP (MMP-14, -15, -16 and
-24, respectively). These enzymes are characterized by a long
hydrophobic sequence followed by a short cytoplasmic tail which is
involved in numerous cellular events, such as the activation of MERK/
ERK and src-tyrosine kinase pathways or the protein trafﬁcking to
discrete regions of the cell surface [44,45]. Moreover, it has been
reported that the cytoplasmic domain of MT1-MMP is essential for the
regulation of protease activity through a dynamin-mediated process
of internalization in clathrin-coated vesicles [46]. Besides their
capacity to cleave a variety of substrates including ECM components,
these membrane-associated MMPs are the major physiological
activators of proMMP-2 [47]. MT-MMPs are expressed by different
tissues under normal conditions, but they are also frequently
upregulated in tumors. Thus, MT1-MMP expression has been asso-
ciated with poor prognosis in several types of cancer [48, 49] and its
overexpression strongly promotes cellular invasion and experimental
metastasis [50,51]. Likewise, MT-MMPs have been involved in the
formation of new blood vessels in both physiological and pathological
conditions [47]. On the other hand, MT4-MMP and MT6-MMP (MMP-
17 and -25, respectively) constitute the second subgroup of mem-
brane-type MMPs which are bound to the cell surface via a GPI-
anchor. MT4-MMP is expressed in brain, colon, ovary, testis, and
leukocytes [52], whereas MT6-MMP is predominantly expressed in
leukocytes, lung and spleen [53]. MT4-MMP has shown a low
enzymatic activity against ECM components, and its contribution to
ECM turnover seems to be indirectly mediated by its ability to activate
aggrecanase-1 (ADAMTS-4) [54]. In contrast, MT6-MMP is able to
process gelatin, collagen IV, ﬁbronectin, ﬁbrin, and proteoglycans [55].
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recent data have detected the expression of MT4-MMP andMT6-MMP
in breast and colon cancer, respectively, and, in both cases, these
MMPs appear to be associated with tumor growth [56].
2.4.3. Type II transmembrane MMPs (MMP-23A and -23B)
MMP-23AandMMP-23Bhave identical aminoacid sequence, but are
encoded by distinct genes in the human genome. These proteases are
unique among thematrixin family because they lack the signal peptide,
the cysteine-switch motif and the hemopexin domain characteristic of
all MMPs, but contain cysteine-array (CA) and immunoglobulin (Ig)
domains in their shortened C-terminal tail. Besides, their type II
transmembrane domain is located at the N-terminal of the propeptide.
Expression analysis has demonstrated that MMP-23 is predominantly
produced by ovary, testis, and prostate, suggesting that this MMP may
play a specialized role in reproductive processes [57]; however, the in
vivo functions of this protease still remain undetermined.
3. Gene evolution and genomic organization of MMPs
Comparative genomic analyses have indicated that the impressive
diversity characteristic of the family of vertebrate MMP genes mainly
derives of a series of evolutionary events that occurred during early
stagesof vertebrate emergence.Nevertheless, these comparative studies
have also revealed amore ancient origin for these endopeptidaseswhich
predates the emergence of vertebrates. Thus, the identiﬁcation of plant
MMPs orthologues to both vertebrate and invertebrate MMPs clearly
supports the proposal of an ancient evolutionary history for these
enzymes. Moreover, the ﬁnding that MMPs in plants and invertebrates
have a closer relationship between them than with vertebrate MMPs,
coupled with the absence of hemopexin domains in their structure,
suggests that they could be modern representatives of an ancient MMPFig. 2. Evolution of MMPs. Schematic representation of key evenancestor, common to the three groups [58]. Likewise, it is tempting to
speculate that the earliest forms of MMPs were based on very simple
architectural designs conformed by catalytic devices without any
ancillary domains. These primitiveMMPswere subsequently increasing
their complexity through gene fusion events that led to the incorpora-
tion of the variety of modules currently exhibited by most family
members. It is also remarkable that most MMP genes found in
vertebrates have an orthologue in Ciona intestinalis, one of the closest
invertebrate relatives of vertebrates [59]. Thus, these enzymes likely
evolved before the divergence between the vertebrate and urochordate
lineages (Fig. 2). Prior to the emergence of vertebrates, theMMP family
had remained relatively stable throughout evolution as assessed by the
low number of conservedMMP genes present in protostomes (2MMPs
in Drosophila melanogaster) [60] and urochordates (5 MMPs in C.
intestinalis) [59]. Nevertheless, it is noteworthy the presence in the sea
urchin genome of at least 26 MMP genes with signiﬁcant similarity to
vertebrate MMPs, although they are clustered together and separated
from vertebrate MMP groups. These ﬁndings suggest that MMP genes
found in the last common ancestor to vertebrates and echinoderms
underwent independent duplication and divergence, following separa-
tion of these two groups [61]. Thus, and as discussed above, it appears
thatMMP vertebrate geneswere ampliﬁed from a commonprotostome-
deuterostome ancestor (Fig. 2).
The major evolutionary event in the generation of the MMP gene
repertoire of vertebrateswas thewidespread duplication of pre-existing
genes (Fig. 2). In particular, most MMP subfamilies show a further
expansion along the early teleost lineage. Nevertheless, it should be
noted that both teleost- and tetrapod-speciﬁc duplications have
occurred after the divergence of both lineages. The expansion in teleosts
of MMP orthologues related to human MMP7 and MMP20, an
evolutionary event likely linked to the continuous teeth replacement
in these vertebrates, is remarkable. Similarly,MT-MMP genes underwentts occurring throughout the evolutionary history of MMPs.
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MT-MMPs compared to 6 MT-MMPs in humans [59]. In contrast, there
are no orthologues to human MMP19, -26 and -28 in the zebraﬁsh
genome, although the presence of these genes in some invertebrates
strongly suggests that they have been speciﬁcally lost in the teleost
lineage. Interestingly, there are several tetrapod-speciﬁc innovations
within theMMP gene family. This is the case ofMMP26which has only
been detected in humans and other primates like chimpanzee,
orangutan and rhesus monkey genomes, strongly suggesting that this
small MMP is the result of a recent evolutionary event circumscribed to
the primate lineage [62]. Another remarkable innovation occurred
during early evolution of tetrapods is the introduction of CA and Ig-like
domains inbothhumanMMP23genes, sincezebraﬁshhas anorthologue
for this gene which lacks these C-terminal domains. Furthermore, the
identiﬁcation of a single MMP23 copy in rodent and chimpanzee
genomes, suggests that the two human copies evolved from a recent
duplication event in the human lineage. The presence of two almost-
identical genes (CDC2L1 and CDC2L2) adjacent to both human MMP23
genes provides additional support to the idea that this region has been
speciﬁcally duplicated in the human lineage [62]. Interestingly, recent
studies have also found two putative MMP23 copies in the Xenopus
genome. The observation that one of these genes is closer to its human
orthologue than to its Xenopus paralogue, has suggested that MMP23
might have duplicated before the separation of amphibians and
mammals, an event that was then followed by the loss of one copy of
this mammalian gene, which emphasizes the relevance of genomic
losses during the evolutionary history of mammals [63,64].
In any case, and beyond these speciﬁc changes affecting individual
MMP genes, the most prominent evolutionary event among those
giving rise to the current MMP gene families was an extensive gene
tandem duplication in the tetrapod lineage (Fig. 2). Accordingly,
several members of the MMP family have likely evolved from a single
gene similar to zebraﬁsh MMPLe which, in successive rounds of
duplications, led to the formation of a genomic cluster ofMMPswhose
organization is preserved from amphibians to mammals. The sinteny
of the common MMP genes within this cluster is also conserved
among all species of sequenced mammals to date, from platypus to
human [65]. This MMP cluster is not composed of the same members
in the different organisms, as there are species-speciﬁc enzymes
encoded in the cluster and distinct events involving loss- and gain-of-
certain MMPs have occurred in the different genomes. Thus, the gene
encoding collagenase-4 (MMP18) has only been identiﬁed in frog,
whereas MMP20 (coding for enamelysin) has not been found in
chicken because its lack of teeth makes unnecessary the occurrence of
an enzyme involved in enamel formation. Likewise, a rodent-speciﬁc
duplication event has generated two MMP1 copies, MMP1a and
MMP1b [2,66]. The human cluster is located at chromosome 11q22
and contains MMP13, MMP12, MMP3, MMP1, MMP10, MMP8, MMP27,
MMP20, and MMP7 (Fig. 3). The fact that most of these MMPs are
able to target protein components of the ECM, coupled with the wide
number of ECM components present in most vertebrates, suggests
that a co-evolution event could have played a role in this process [67].
As an illustrative example supporting this idea, there are three colla-
genolytic enzymes encoded in this cluster (MMP-1, MMP-8 andMMP-
13) which have preferential activity against one of the three major
types of ﬁbrillar collagen: MMP-1 is mainly active against type III
collagen, MMP-8 targets type I collagen and MMP-13 preferentially
cleaves type II collagen [68]. MMP genes are not exclusively clustered
in a few regions of the vertebrate genomes as they are widely
distributed along the different chromosomes. This is the case of
human MMPs which are distributed in 10 distinct chromosomes
(Fig. 3). It is also noteworthy the localization of functionally related
MMP genes in different chromosomes, as illustrated for the two
gelatinase genes MMP2 and MMP9 which map at chromosomes 16
and 20, respectively. Moreover, the sequences encoding the catalytic
and hemopexin domains of both gelatinases are not clusteredtogether. Collectively, these observations suggest that these
MMPs likely evolved in parallel, indicating that the selection pres-
sure was distinct in the course of the diversiﬁcation of this family of
metalloproteinases [58].
In addition to mechanisms based on gene duplication, the
evolution of MMP genes has also been driven by exon shufﬂing and
duplication of protein modules to form new arrangements. In this
regard, it is well known that proteases link their catalytic domains to a
range of specialized functional modules generating an extraordinary
diversity of specialized enzymes [69]. In the case of MMPs, some of
these modules, including the hemopexin, Ig-like and ﬁbronectin
domains, act as ancillary domains that allow these enzymes to interact
with other proteins and expand their functional relevance (Fig. 1).
Nevertheless, evolution has also progressed in the reverse direction as
illustrated by the case of the hemopexin domain which is present in
most MMPs, but was speciﬁcally lost in both members of the
matrilysin subfamily (MMP-7 and MMP-26) [2].
In summary, genomic studies are consistent with the idea that most
part of the large complexity currently observed in MMP families of
tetrapods arose during early stages of vertebrate evolution. It is also
likely that these enzymes ﬁrst appeared as simple proteins with a
catalytic domain that, after several rounds of duplication, gene fusion
and exon shufﬂing events, acquired a more complex structural
architecture based on the introduction of additional functional domains
of diverse sizes and shapes. The incorporation of ancillary domains,
coupled with the subsequent parallel evolution of each member of the
family, originated the increasingly specialization of these proteases. The
ampliﬁcation in the number of genes that has occurred from C.
intestinalis to H. sapiens, together with the presence of duplicated
genes in paralogous regions of the genome, suggests that one or two
rounds of whole genome duplication took place. In the case of
mammalianMMP genes, these processes of duplication and reorganiza-
tion have led to a wide distribution of these genes into different
chromosomes, although a number of them are clustered in a speciﬁc
genome region. The large complexity arisen during MMP evolution
made also necessary the evolutionary incorporation of precisemechan-
isms of regulation to control the expression and activity of these
enzymes. These regulatory mechanisms, which are only partially
understood, will be discussed in the next sections of this review.
4. Regulation of MMP gene expression
MMP gene expression is primarily regulated at the transcriptional
level, which usually results in low basal levels of these enzymes in
normal physiology. Most members of the MMP family share common
cis-elements in their promoter sequences, which allow a tight control
of cell-speciﬁc expression. As a result,MMPs are often co-expressed or
co-repressed in response to multiple stimuli, including inﬂammatory
cytokines, growth factors, glucocorticoids or retinoids [70]. This res-
ponse at the transcriptional level occurs several hours after exposure
to a stimulus, suggesting thatMMP promoters are downstream targets
within signaling pathways of early response genes, which are induced
shortly after cellular stimulation and in the absence of new protein
synthesis. These early response genes encode signaling proteins that
phosphorylate the different transcription factors, which are then able
to bind the promoters of MMP genes. These signaling intermediates
involved in the activation of transcription factors include the nuclear
factor kappa B (NF-κB), the mitogen activated protein kinases
(MAPK), the signal transducers and activators of transcription
(STAT) and the Smad family of proteins. These intermediates belong
to signaling pathways that are activated by a large variety of ligands,
such as IL-1β, TNF-α and oncostatin M. The blockade of these
signaling pathways by decreasing the synthesis of some downstream
mediators, by sequestering the transcription factors to prevent their
binding or by inhibiting their phosphorylation, may repress the
expression of MMP genes [71]. Some of the key transcription-binding
Fig. 3. Genomic organization of human MMPs. Exon structure of human MMP genes and their chromosomal location in human (black numbers) and mouse (in parentheses). Domains are shown in the indicated code colour.
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teins (AP) -1 and -2 sites, the polyomavirus enhancer-A binding
protein-3 (PEA3) site, the NF-κB site, and the STAT site [72]. Interes-
tingly, MMPs that are co-regulated in their expression under certain
conditions share several transcription-binding sites in their promoter
sequences, whilst functionally related MMPs, such as gelatinases
(MMP-2 and -9) or collagenases (MMP-1 and -8), differ greatly in the
composition of the cis-elements present in their respective promoter
regions (Fig. 4).
4.1. AP-1 response elements
The AP-1 site appears to be the major mediator of the regulation of
MMP genes. Thus, most MMP promoters harbor an AP-1 site in the
proximal promoter, located close to a typical TATA box (Fig. 4).
However, the composition of the AP-1 complex itself, as well as the
juxtaposition of transcription factor binding sites, may determine the
speciﬁcity among different genes [73]. An example of AP-1 regulation
can be found in the MMP1 promoter. Thus, it has been reported that
inﬂammatory cytokines enhance the trans-activation of MMP1
through the MAPK signaling pathway, by increasing the levels of
different AP-1 proteins, such as c-jun, jun-B and c-fos [74]. In this
sense, c-Jun has been described to be an independent activator of
MMP1 expression as demonstrated by its capacity to induce minimal
MMP1 promoter activity as a Jun/Jun homodimer. However, jun-B
requires the interaction with other members of the AP-1 family, such
as c-fos, to promote MMP1 transcription [75]. Likewise, these
heterodimers may form ternary complexes with additional transcrip-
tion factors, thus increasing their binding capacity to the regulatory
cis-elements [76].
4.2. PEA3 response elements
The PEA3 site binds members of the Ets family of oncoproteins. In
several MMPs, the PEA3 site is located adjacent to the AP-1 site, and
both may act cooperatively to promote MMP production by cancer
cells, allowing their migration and invasiveness [77]. In this sense,Fig. 4. Regulatory elements in the promoter regions of humanMMP genes. Transcription star
are represented within boxes. The relative positions of the different binding sites are not dralthough PEA3 proteins have been shown to trans-activate artiﬁcial
promoter constructs only containing the PEA3 element, they do not
usually dimerize and bind to DNA alone, but prefer to form complexes
with other transcription factors, thereby enhancing their effect [78].
Consistently, PEA3 sites are able to bind multiple Ets factors and these
proteins contribute to provide the required speciﬁcity. For example,
Ets1 increases MMP1 expression through c-Jun, whereas ErgB
enhances the trans-activation of this promoter only via JunB, and
Pu1 represses its induction by both c-Jun and JunB. These examples of
functional interaction between Ets and AP-1 factors indicate thatMMP
gene expression may be speciﬁcally modulated in situations such as
tumor cell growth and invasion, where both types of factors can be
simultaneously induced [79, 80].
4.3. NF-κB response elements
The NF-κB pathway is involved in the regulation of several MMPs,
upon activation by a number of growth factors and cytokines in
pathological conditions, such as arthritis,muscular disorders and cancer
[81–83]. In addition, this family of transcription factors, including NF-
κB1 and 2, RelA, c-Rel, and Rel-B, can interact with other proteins to
increase MMP expression. Thus, IL-1β-induced MMP1 gene expression
in chondrocytes requiresNF-κB homodimers binding to Bcl-3 to activate
MMP1 transcription [84]. Likewise, interaction between juxtaposed sites
allows the speciﬁc expression of this MMP in osteosarcoma and
hepatoma cells after its stimulation with TNF-α, which increases the
activity of both NF-κB and Sp-1 transcription factors [85].
4.4. STAT response elements
STAT proteins are transcription factors that translocate to the
nucleus following tyrosine phosphorylation and dimerization [86].
This family of proteins frequently collaborates with different factors to
promote gene-speciﬁc expression. Thus, epidermal growth factor
(EGF)-mediated-MMP1 transcription through STAT-3 is stimulated by
the binding of c-Jun to the AP-1 element, which is located close to the
STAT site [87]. It seems that the stimulation of the STAT pathway is ant sites are indicated with a bent arrow and the main functionally validated cis-elements
awn to scale.
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pathological conditions [71]. Similarly, a complex composed of c-Jun/
Fra-1 and STAT-3 proteins has been shown to bind the promoter-
proximal AP-1 site of MMP9, thereby conﬁrming the existence of a
STAT binding site in juxtapositionwith the AP-1 site [88]. Interestingly,
activation of STAT proteins does not always induceMMP gene expres-
sion. Thus, MMP9 and MMP13 expression can be repressed as a result
of sequestration of co-activators, such as CBP/p300, by STAT proteins,
which impair their binding to cis-elements on the promoters [89].
4.5. Other regulated cis-elements
MMP7 is regulated by Wnt signaling through the binding of beta-
catenin and its partners like Tcf/Lef-1, to its promoter region [90]. Tcf/
Lef-1 also synergizes with other factors, particularly those that bind to
PEA3 or AP-1 sites, to enhance the expression of MMP7 in colorectal
tumors [91]. Similarly, soluble E-cadherin fragments increase MMP14
expression in lung cancer cells under the control of the beta-catenin
pathway [92]. On the other hand, MMP13 expression is stimulated by
p38 signaling through the recruitment of AP-1 proteins and the
chondrocyte/osteoblast-speciﬁc transcription factor Runx-2, empha-
sizing the tissue-speciﬁc mechanisms regulating MMP13 gene ex-
pression [93,94].MMP9 expression is also regulated by Runx2 binding
elements, which agrees with its proposed role in bone remodeling
during endochondral ossiﬁcation [95]. MMPs are also regulated by
Smads, a small family of co-regulatory proteins that can enhance or
inhibit TGF-β-mediated gene expression, providing a mechanism by
which TGF-β may play a dual role in the regulation of MMP genes
during connective tissue remodeling and cancer [96–98]. As men-
tioned above, TGF-β counteracts the IL-1β-induced MMP1 transcrip-
tion through activation of Smad2 and Smad3, which, in turn, are able
to block the binding of the CBP/p300 co-activator [99]. Opposite to
MMP1, MMP13 gene expression is induced by TGF-β in connective
tissue cells, through the activation of Smad3 and the participation of
MAPK signaling pathways [96,100]. It is also remarkable that the
proximal promoters of several MMPs have multiple GC boxes with
ability to bind Sp-1 and Sp-3 transcription factors (Fig. 4). Interes-
tingly, some genes such as MMP2, MMP14 and MMP28, do not harbor
TATA box or otherMMP-characteristic cis-regulatory elements in their
proximal promoters, which can explain the fact that they are constitu-
tively expressed and can only be occasionally induced by certain
growth factors or cytokines [70]. In summary, the integration of mul-
tiple signaling pathways controlling MMP transcriptional regulation,
provides a wide range of potential interactions between transcription
factors, which may explain how tissue speciﬁcity is achieved among
the different members of the MMP family.
5. Epigenetic regulation of MMPs
In general, MMPs have been considered as inducible genes on the
basis of a series of experiments that have demonstrated that their
expression is transient upon exposure to external stimuli. However, in
cancer, both tumor and peritumor cells constitutively express high
levels of MMPs, indicating that additional mechanisms are involved in
their regulation. Thus, epigenetic mechanisms, such as DNA methyla-
tion or histone acetylation, may contribute to modulate both acti-
vation and repression of MMP gene expression.
Methylation of CpG islands in the promoter region of multiple genes
has been widely recognized as an efﬁcient mechanism of repressing
transcription. Thus, an inverse correlation between promoter methyla-
tion ofMMP9 and expression levels has been found in lymphoma cells,
providing evidence that methylation of the promoter region is
functionally relevant forMMP9 gene expression [101]. Likewise,MMP2
hypomethylation increases its expression and contributes to cancer cell
invasiveness and tumorigenesis [102]. Similarly, a colon cancer cell line
defective in two key DNA methytransferases (Dmt-1 and Dmt3b)showed increased expression ofMMP3. In addition, treatment of normal
colorectal cellswithDNAmethyltransferase inhibitors recapitulated this
effect, whereas in vitro methylation of the MMP3 promoter suppresses
its transcriptional activity. However, this increased expression ofMMP3
appears to be cell-speciﬁc since treatmentwith the samedemethylating
agent failed to induceMMP3 transcription in a lymphoma cell line [103].
An additional level of epigenetic control of gene expression derives
from post-translational modiﬁcations of histones through acetylation
processes. Histone acetyl transferases (HAT) are the enzymes respon-
sible for the reversible union of acetyl groups to histones (mainlyH3and
H4), leaving the chromatin in amore relaxed state that allows the access
of transcription factors and other transcriptionalmachinery to promoter
regions [104]. The effect of the chromatin remodeling in the control of
MMP expression has been reported for some MMP genes. Thus, Yan et
al. [105] ﬁrst showed that MTA1, a component of the NuRD repression
complex, binds to the MMP9 promoter causing the recruitment of
histone deacetylase (HDAC) 2 and the decrease of H3/H4 acetylation
levels, which ﬁnally results in a reduction of DNA accessibility and gene
expression. Likewise, MMP10 expression is repressed as a result of the
recruitment of HDAC7–MEF2 complex to theMEF2-binding site present
in the MMP10 promoter [106]. Similarly, the induction of MMP1 and
MMP13 by IL-1α and oncostatin M is almost completely abolished by
two independent HDAC inhibitors [107]. Nevertheless, acetylation per se
is not sufﬁcient to induceMMP1 expression inhuman glioblastomacells,
since treatment with HDAC inhibitors had no effect in MMP1 mRNA
levels despite an increase in local H3 acetylation at theMMP1 promoter
is observed. This ﬁnding suggests that MMP1 transcription requires a
prior activation of certain transcription factors, such as c-Jun, c-Fos, TBP,
RNAPII and SET9, that bind the MMP1 promoter and recruit CBP/p300
and RSK2 histone acetyltransferases,ﬁnally leading to a permissive state
of DNA for transcription initiation [108]. In this sense, the histone
acetyltransferase p300 has been recently demonstrated to play a key
role in ultraviolet-induced MMP1 promoter activity [109]. Likewise,
analysis of the sequential assembly of transcription complexes onMMP9
promoter has revealed that, after PMA-induced MMP9 expres-
sion, transcription factors, chromatin-remodeling complexes, and co-
activators are recruited to the pre-assembled MMP9 promoter in a
stepwise and coordinatedmanner, which is dependent on the activation
of the MEK-1/ERK and NF-κB signaling pathways. Interestingly, both
HDAC1 and HDAC3 are pre-assembled on the MMP9 promoter as
repressive complexes in a basal cell state, being removed upon PMA
stimulation [110]. Additional studies have supported the role of
transcription factors in the control of gene expression by recruiting
chromatin-remodeling complexes to the promoters and the synergy
among these co-activators [111,112]. Taken together, theseﬁndings show
the interconnection between the diverse MMP gene regulatory
mechanisms operating at the transcriptional level, and conﬁrm that
this complexity is increased by cell-speciﬁc induction. Nevertheless,
further studies will be required to fully understand the epigenetic
mechanisms that controlMMP gene expression.
6. Post-transcriptional regulation of MMPs
Although MMPs are mainly regulated at the transcriptional level, a
series of post-transcriptional events have been recently described as
relevant mechanisms in the regulation ofMMP expression.MMP trans-
cripts harbor speciﬁc sequences in their 5′- or 3′-untranslated regions
(UTRs), which are potential targets of different UTR-binding proteins
with ability to stabilize or destabilize these mRNAs. Thus, the ratMMP9
transcript contains several copies of AU-rich elements (ARE) within its
3′-UTR, which are important determinants for RNA turnover [113]. In
this regard, it has been reported that IL-1β-inducedMMP9 expression is
enhanced by theATPanalog ATPγS through an increase in the bindingof
the HuR stabilizing factor to the AREmotifs present in the 3′-UTR of the
MMP9 mRNA, providing protection against rapid degradation [114].
Likewise, oncogenic Ras-dependent MERK/ERK signaling maintains
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with α3β1 integrinwhich promotes mRNA stability [115]. In contrast, a
decline in the MMP9 mRNA levels has been reported to be caused by
nitric oxid in mesangial cells, which is responsible for the reduction of
the HuR protein content and its subsequent binding to the 3′-UTR of
MMP9 transcripts [113]. Recent studies have also shown that IL-10
contributes to improve the ﬁbrotic processes that follow acute
myocardial infarction, by reduction of MMP9 expression via repression
of HuR protein [116]. Parallel studies have revealed that cortisol induces
MMP13 steady state mRNA in osteoblasts by increasing protein binding
to ARE elements in its 3′-UTR region [117].
In addition to mRNA stability, regulation of translational efﬁciency
may be also a mechanism for controlling MMP expression. Thus,
elevated binding of nucleolin to the 3′-UTR of humanMMP9mRNA has
been observed in ﬁbrosarcoma cells in response to an iron chelator.
Nucleolin recruits inactive MMP9-mRNA complexes into the rough
endoplasmic reticulum, enhancing the efﬁciency of MMP9 translation
[118]. Likewise, more rapid MMP9 translation has been described in
murine prostate carcinoma cells where an increase in the binding of
mRNA to polysomes results in elevated MMP-9 protein levels [119].
Finally, recent experimentalwork has demonstrated thatmicroRNAs
(miRNAs)may also participate inMMP regulation. Studies on the role of
miRNAs in the regulation of eukaryotic genes have impressively in-
creased over the last few years. These small RNA molecules are capable
of negatively regulatinggeneexpression at the post-transcriptional level
through either translation repression or degradation of their mRNA
targets. Bioinformatic analyses have predicted potentialmiRNA-binding
sites in the 3′-UTR regions of certainMMPs [120]; however, to date, only
one study has demonstrated thatMMPsmay be direct targets ofmiRNAs
[121]. Indeed, the remaining reports in this ﬁeld have only shown how
MMP expression is modulated indirectly through miRNAs that target
genes involved in different signaling pathways responsible for MMP
activation. For instance, MMP2 expression is upregulated by mir-21 in
response to the high levels of phospho-Akt caused by the knockdown of
PTENmRNA,which is targeted by thismiRNA aftermyocardial infarction
inmice [122]. Similarly, mir-21 downregulates TIMP3 (tissue inhibitor of
metalloproteinase3),which, in turn, leads to the activation ofMMPs and
the subsequent promotion of cancer cell invasiveness [123]. Likewise,
MMP-13 secretion is modulated by mir-9 in human osteoarthritic
processes, through the reduction of TNF-α [124]. Nevertheless, and
basedon the growing relevanceofmiRNAs in the regulation of biological
processes, it is tempting to speculate that further work in this ﬁeld will
reveal the occurrence of additionalmiRNAswith ability to target speciﬁc
MMPs, thus contributing to regulate their functions in the different
physiological and pathological contexts in which they are implicated.
7. Mutations in MMP genes and human diseases
There are several hereditary disorders caused by autosomal muta-
tions in humanMMP genes. All of them result from the loss-of-function
of the corresponding protease activity, which ﬁnally leads to marked
deﬁciencies in the turnover of speciﬁc ECM components. The ﬁrst
MMP mutation associated with a human inherited disease was identi-
ﬁed in two consanguineous Saudi Arabian families with nodulosis–
arthropathy–osteolysis syndrome (NAO), an autosomal-recessive form
of multicentric osteolysis. A genome-wide analysis had previously
identiﬁed the chromosome 16 as carrier of the disease gene, and sub-
sequent studies narrowed the critical region close to the gene encoding
MMP-2 [125]. To date, several MMP2 mutations have been reported in
three different skeletal disorders, collectively known as inherited
osteolysis syndromes and characterized by progressive resorption of
bones. The common pathogenic mechanism in the three genetic
disorders seems to be the loss of MMP-2 activity, as no detectable
MMP-2 enzymatic activity can be found in serum and ﬁbroblasts from
patients homozygous for mutations in this gene. Thus, the Y244X
mutationdescribed in the abovementionedNAOsyndrome introduces apremature stop codon that removes most functional protein domains
[125]. The E404K mutation observed in patients with Winchester
syndrome changes the key glutamate residue in the catalytic domain of
theMMP-2 protein and leads to a complete loss of its peptidase activity
[126]. Additionally, two MMP2 heterozygous mutations have been
reported in a patientwith Torg syndrome. Theﬁrstmutation, R101H, has
also been found in patients with NAO syndrome and affects a residue
adjacent to the key cysteine in the propeptide, thereby resulting in
destabilization of the cysteine-zinc interaction. The second mutation,
1957delC, causes a frameshift which creates a truncated nonfunctional
protein. In combination, the two mutations should cause the complete
loss of MMP-2 activity in this patient with Torg syndrome [127]. Based
on the ﬁnding that all these mutations abolish MMP-2 proteolytic
activity, NAO, Winchester and Torg syndromes have been considered
allelic disorders that form a continuous clinical spectrum.
Parallel studies have revealed that another genetic disease of bone
metabolism is caused by mutations in a humanMMP gene. Thus, muta-
tions in theMMP13 gene are responsible for theMissouri type of human
spondyloepimetaphyseal dysplasia (SEMD), an autosomal dominant
disorder characterized by defective growth and remodeling of vertebrae
and long bones. The F56S missense mutation results in an abnormal
intracellular autoactivation and autodegradation of themutantMMP-13
protein, with the resultingMMP-13 deﬁciency. Nevertheless, before it is
fully proteolytically degraded, the mutant protein intracellularly de-
grades the MMP-13 product of the wild-type allele, explaining the
haploinsufﬁciency of the gene and thereby, the dominant phenotype of
the disorder [128].
Finally,MMP-20or enamelysin is the thirdMMP familymember that
has been implicated in a human inherited disease: autosomal-recessive
amelogenesis imperfecta (ARAI). The ARAIs are a group of clinically and
genetically heterogeneous disorders that affect enamel development,
resulting in abnormalities in the amount, composition, and structure of
enamel. To date, at least three different MMP20 mutations have been
reported in families with ARAI. The ﬁrst identiﬁed mutation was found
at the 3′-end of intron 6, where AG changed to TG, causing defective
splicing events that introduce an upstream translation termination
codon in the transcript [129]. Likewise, the W34X mutation is a single
nucleotide substitution that generates a stop codon in exon 1 ofMMP20
[130]. The third characterized mutation in this gene (H226Q) changes
one of the three-conserved histidine residues in the catalytic domain,
thereby destroying the zinc-ligand site required formetal binding [131].
Thus, all MMP20 mutations described to date lead to complete lack of
proteolytic activity on amelogenin, the in vivo substrate for enamelysin.
In addition to these interesting cases of MMP alterations in inhe-
rited human diseases, very recent studies have shown that these genes
can also be target of sporadic mutations in cancer. The ﬁrst indication
that MMPs could be mutated in cancer derived from the observation
thatMMP2was one of the so-called CAN genes found to be mutated in
a small set of breast and colorectal cancers [132]. Further studies have
extended the mutational analysis ofMMPs to other malignant tumors
with the ﬁnding that some family members including MMP8, MMP14
andMMP27 aremutated albeit at low frequency in differentmalignan-
cies including lung carcinomas and melanoma (http://www.sanger.
ac.uk/genetics/CGP/cosmic/). These yet unpublished results, together
with those recently obtained in the ADAMTS family of metalloprotei-
nases, have supported the innovative proposal that extracellular pro-
teases are direct target of genetic mutations in cancer [6, 133].
Nevertheless, to date, no functional analysis have been reported to
validate these preliminary genetic ﬁndings and further studies will be
necessary to provide functional support to the putative relevance of
MMPmutations during cancer progression.
8. MMP polymorphisms and human disease susceptibility
Polymorphisms in human MMPs can modify gene expression by
altering the interaction between transcription factors and transcription-
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lower transcriptional activity and having dual roles in disease. A number
of functional polymorphisms have been identiﬁed in the promoters of
MMP genes and several of them are associated with increased suscep-
tibility to the development of different pathologies and their prognosis
(Table 1). Thus, correlations between single nucleotide polymorphisms
(SNPs) and cancer susceptibility have been reported for several MMPs.
The ﬁrst described SNP for MMP1 is an insertion of a G residue
at −1607 in the MMP1 promoter which creates a binding site for Ets
transcription factors adjacent to an AP-1 site located at−1602. The 2G
allele leads to higher levels of MMP1 mRNA and protein in several
tumors, and is associated with increased lung and colorectal cancer
susceptibility [134,135]. The association between 2G/2G genotype and
poor prognosis in patients with melanoma or breast and ovarian car-
cinomas has also been observed, although data are inconsistent for all
tumor types [136–138]. Furthermore, the−1607 1G/2G polymorphism
has been implicated in other non-tumor pathologies, such as ﬁbrotic
disorders. Thus,MMP1 is overexpressed in idiopathic pulmonaryﬁbrosis
and the frequency of 2G/2G genotype is higher in patients with this
disease [139]. The 2G/2G genotype may also contribute to cirrhosis
[140].
In the case ofMMP2, three functional SNPs have been mapped in its
promoter region. Two of them are C toT transitions located at−735 and
−1306, which abolish Sp1 binding, with the T allele being associated
with diminished promoter activity. Interestingly, these SNPs are in
linkagedisequilibriumwith the−1306T/−735Thaplotype resulting in
a lower promoter activity comparing with the single−1306 or−735 T
allele haplotypes.High riskof developing lungandesophageal cancer for
−1306CCor−735 CC genotype carriers has been reported, suggesting a
protective role for −1306 T and −735 T alleles. Importantly, a greater
risk of lung and esophageal cancer has been associated with−1306 C/
−735C haplotype [141,142]. The third SNP found in theMMP2 promoter
is a G to A transition at −1576, which disrupts estrogen receptor α
binding, and also results in lower transcriptional activity [143].
A functional SNP in the MMP3 promoter has also been described,
but in this case, the insertion of an A residue at−1171 generates a 6A
allele that enhances the afﬁnity for the repressor ZBP-89 and decreases
MMP-3 protein levels. This 6A allele would play a protective role in
lung, oral and breast cancer, whereas the 5AMMP3 allele is linkedwith
an increased risk for these cancers [144–146]. Additional studies have
suggested that the 6A/6A MMP3 genotype is associated with worse
rheumatoid arthritis outcome aswell aswith atherosclerotic processes
[147,148]. On the other hand, two polymorphisms have been found in
the MMP7 promoter region, an A to G substitution at position −181Table 1
Functional polymorphisms in MMP promoters.
Gene Polymorphism Promoter
activity
Associated pathology
Tumor-disease
MMP1 −1607 1G/2G Higher ↑ Risk: lung [134] and colorectal [135] cancer
Poor prognosis: breast [136] and ovarian [137] canc
cutaneous malignant melanoma [138]
MMP2 −1575 G/A Lower Breast cancer [143] (in vitro MCF-7 cells)
−1306 C/T Lower ↓ Risk: esophageal [141] and lung [142] cancer, gas
adenocarcinoma [204], oral squamous cell carcinom
−735 C/T Lower ↓ Risk: esophageal [141] and lung [142] cancer
MMP3 −1171 5A/6A Lower ↓ Risk: lung [144] breast [145] and oral [146] cance
MMP7 −181 A/G Higher ↑ Risk: gastric [150], cervical [151] and oral [152] c
squamous cell carcinoma and non-small cell lung c
MMP8 −799C/T Higher Better prognosis: breast cancer [155]
−381A/G Higher
+17C/G Higher ↓ Risk: lung cancer [156]
MMP9 −1562 C/T Higher ↑ Risk: oral cancer [207]
(CA)n
microsatellite
Higher≥20
CA repeats
↑ Risk: bladder cancer [163]
MMP12 −82A/G Lower Poor prognosis: bladder cancer [163]and a C toT substitution at position−153, both of them increasing the
promoter activity [149]. A relationship of the −181 G allele with
increased susceptibility for gastric, cervical, lung, oral and esophageal
cancer has also been described [150–153].
For the MMP8 gene, three functional SNPs (−799C/T, −381A/G
and +17C/G) have been identiﬁed. The haplotype with the three less
frequent alleles of these SNPs increases MMP8 promoter activity in
trophoblast cells and is associatedwith higher risk of pretermpremature
rupture of membranes [154]. Individually, the G allele of the +17 C/G
SNP is linked to a decreased risk for lung cancer, and the−799 T to lower
susceptibility to metastasis and better survival in breast cancer patients
[155,156]. These results are in agreement with the proposal that MMP-8
has antitumor properties [157–159]. With respect to MMP9, a poly-
morphism has been observed in the promoter region located at position
−1562. This variant is a C/T transitionwhich leads to a higher promoter
activity in the T allele which has been associated with increased
susceptibility to atherosclerosis [160], abdominal aortic aneurysm [161]
andmyocardial ischemia [162]. Additionally, amicrosatellite polymorph-
ism of variable number of CA repeats (from 14 to 25 at position−131)
and localized immediately adjacent to the proximal AP-1 binding site,
has been described to increase the transcriptional activity of theMMP9
gene in a manner proportional to the number of CA repeats. TheMMP9
microsatellite (≥24 CA repeats) has been associatedwith a higher risk of
bladder cancer invasiveness [163]. This polymorphism has also been
associated with susceptibility to a number of conditions, including
atherosclerosis [164], multiple sclerosis [165], aneurysmal disease [166],
and age-related macular degeneration [167]. For MMP12, an A to G
substitution at position−82, located in the AP-1 binding site, has been
linked to decreased expression in vitro. Several studies have also shown
that the GG genotype is associated with increased bladder cancer
invasiveness and this has been attributed to the loss of putative
angiostatic effects of MMP-12 [163]. Finally, it is important to consider
that MMP polymorphisms may not occur as independent events and
could be associated with other polymorphisms in the genome.
9. Transgenic models for functional analysis of MMPs
Over the last two decades, the generation of genetically modiﬁed
mouse models has become one of the most powerful strategies for
studying gene function in vivo. Genetic engineering approaches have
allowed the modulation of gene expression through gain-of-function
(transgenic) or loss-of-function (knock-out) in vivo models. To date,
many transgenic and knock-out mice (Table 2) have been generated to
analyze the effects of altering MMP activity in a variety of physio-Non-tumor disease
↑ Risk: idiopathic pulmonary ﬁbrosis [139]
er, Poor prognosis: cirrhosis [140]
tric cardia
a [205]
↓ Risk: lumbar disc disease [206]
r ↑ Risk: atherosclerosis [147]
Poor prognosis: rheumatoid arthritis [148]
ancer, esophageal
arcinoma [153]
Poor prognosis: atherosclerosis [149]
↑ Risk: preterm premature rupture of membranes (haplotype) [154]
↑ Risk: preterm premature rupture of membranes (haplotype) [154]
↑ Risk: preterm premature rupture of membranes (haplotype) [154]
↑ Risk: atherosclerosis [160, 162], abdominal aortic aneurysm [161]
↑ Risk: carotid atherosclerosis [164], multiple sclerosis [165],
cerebral aneurysm [166], age-related macular degeneration [167]
Table 2
Genetically modiﬁed mouse models of MMPs.
Genetically modiﬁed mice Spontaneous phenotype Pathological-induced phenotype
Tumoral Non-tumoral
Haptoglobin-MMP1 Hyperkeratosis [178] ↑ Skin carcinogenesis [178]
Pulmonary emphysema [208]
TypeIγ-GT-MMP2/cmyc Chronic kidney disease [209]
WAP-MMP3 Mammary carcinogenesis [180]
K5⁎-MMP3301.24 ↓ Skin carcinogenesis [210]
SREP-MMP9 ↓ Pulmonary ﬁbrosis [211]
MMTV-MMP14 Mammary carcinogenesis [179]
Mmp2−/−/RIP-TAg ↓ Pancreatic carcinogenesis [212]
Mmp2−/−/ApoE−/− ↓ Atherosclerotic plaques [192]
Mmp3−/−/ApoE−/− ↑ Atherosclerotic plaques [190]
↓ Aneurism formation [190]
Mmp7−/−/ApcMin ↓ Intestinal adenomas [213]
Mmp9−/−/ApoE−/− ↓ Atherosclerotic plaques [191]
Mmp9−/−/K14-HPV16 ↓ Skin carcinogenesis [183]
Mmp9−/−/RIP-TAg ↓ Pancreatic carcinogenesis [212]
Mmp11−/−/MMTV-ras ↓Mammary carcinogenesis [184]
↑ Number of metastasis [184]
Mmp13−/−/ApoE−/− ↑ Atherosclerotic plaques [189]
Mmp14−/−/MMTV-PyMT ↓ Lung metastasis [214]
Mmp1a−/− No overt phenotype (C. Lopez-Otin, unpublished)
Mmp2−/− ↓ Body size [215] ↓ Tumor growth [216] ↑ Arthritis [187]
↓ Bone density [172] ↓ Angiogenesis [216] ↓ Resolution of lung allergic inﬂammation [197]
Altered mammary branching [170] ↓ Acute hepatitis [217]
Mmp2−/−/Mmp9−/− ↓ Resolution of lung allergic inﬂammation [198]
Mmp2−/−/Mmp14−/− Death at birth [176] Resistance to EAE [193]
Mmp3−/− Altered mammary branching [170] ↑ Skin carcinogenesis [218] Impaired contact dermatitis [219]
↓ Acute hepatitis [217]
↑ Arthritis [188]
Mmp7−/− ↓ Innate intestinal immunity [220] Impaired tracheal wound repair [222]
Defective prostate involution [221] ↓ Pulmonary ﬁbrosis [202]
↓ EAE [195]
Mmp8−/− ↑ Skin carcinogenesis [157] ↑ Asthma [199]
↑ Experimental metastasis [158] ↓ Acute hepatitis [223]
↓ EAE [194]
Mmp9−/− Delayed growth plate vascularization [171] ↓ Experimental metastasis [225] ↓ Aortic aneurysms [226]
Defective endochondral ossiﬁcation [171] ↓ Arthritis [187]
Delayed myelinization [224] ↓ Acute hepatitis [217]
Prolonged contact dermatitis [219]
↓ Colitis [227]
Mmp9−/−/Mmp13−/− Shortened bones [169]
Mmp10−/− ↑ Pulmonary inﬂammation and mortality [200]
Mmp11−/− Accelerated neointima formation after vessel injury [228]
Mmp12−/− Delayed myelinization [224] ↓ Pulmonary emphysema [201]
↑ EAE [196]
Mmp13−/− Bone remodeling defects [168, 169] ↓ Hepatic ﬁbrosis [229]
Mmp14−/− Severe abnormalities in bone and connective tissue [173]
Defective angiogenesis [174]
Premature death [173]
Mmp14−/−/Mmp16−/− Perinatal lethality [177]
Mmp16−/− Growth retardation [177]
Mmp17−/− No overt phenotype [230]
Mmp19−/− ↓ Skin carcinogenesis [185] ↑ Induced obesity [185]
↑ Angiogenesis [186]
Mmp20−/− Amelogenesis imperfecta [175]
Mmp24−/− Absence of mechanical allodynia [231]
Mmp28−/− ↑ Macrophage recruitment in lung [232]
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provided the opportunity to validate candidate substrates, which are
the essential partners to uncover protease function [69].
A total of 17 out of the 23 murine Mmp genes have already been
knocked-down. However, despite this broad landscape of gene
targeting, the vast majority of these constitutive knock-out mice
display subtle spontaneous phenotypes (Table 2). Among the three
collagenases, only the deﬁciency in collagenase-3 leads to develop-
mental defects characterized by impaired bone formation and remo-
deling due, in part, to the lack of appropriate type II collagen cleavage
[168, 169]. However, mice deﬁcient in collagenase-1 (C. López-Otín,
unpublished data) or collagenase-2 show no overt physiological
abnormalities [157]. Likewise, the absence of any of the three stro-melysins does not produce major alterations, with the exception of
Mmp3-null mice whose mammary glands show deﬁcient secondary
branching morphogenesis [170]. Deﬁciency in any of the two
gelatinases is also characterized by certain defects in bone biology.
Thus, mice deﬁcient in Mmp9 have delayed long bone growth and
development due to impaired vascular invasion in skeletal growth
plates [171]. In addition, Mmp2 deﬁciency causes disruption of the
osteocytic networks and reduced bone density [172]. Interestingly, the
most severe phenotype among MMP knock-outs is also associated
with defects in skeletal development. In this sense, targeted inactiva-
tion of the Mmp14 gene causes multiple abnormalities in the
remodeling of skeletal and connective tissues, as well as defective
angiogenesis, leading to premature death by 3–12 weeks after birth
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development due to impaired amelogenin processing [175]. Remar-
kably, these bone abnormalities shown in MMP knock-outs pheno-
copy the human skeletal syndromes caused by loss-of-function MMP
mutations [125,128,129]. The remaining Mmp-null mice generated to
date show no major physiological alterations, although it is important
to emphasize that all available MMP knock-out models are constitu-
tive, thus leading to the possibility of enzymatic compensation as a
way to circumvent the absence of the targeted gene. Another possible
explanation for the lack of severe phenotypes inMmp-null mice is the
enzymatic redundancy among different members of the family, which
share many substrates in vitro. The recent generation of double MMP
mutants has supported this hypothesis, and future studies in this di-
rection may also argue for essential roles of certain MMPs in embryo-
nic development, in addition to their known functions in postnatal
tissue remodeling [176,177].
Despite early characterization of MMP knock-outs did not provide
major evidence about thebiological relevanceof this family of proteases,
further analyses of these mouse models challenged by a series of
pathogenic conditions have revealed the essential contributionofMMPs
to a broad number of pathological processes. Among them, over the last
25 years, cancer has been the central disease supporting the promising
ﬁeld of MMPs research. In this sense, the ﬁrst transgenic mouse models
overexpressing different members of the family (Table 2) validated the
initial assumption for the contributory effect of these ECM degrading
enzymes to tumor progression [178–180], since high levels of MMPs
often correlatedwith poor clinical outcome in cancer patients. However,
the generation of new genetically modiﬁed animal models has demon-
strated that certain MMPs, such as MMP-8 or MMP-12, contribute to
tumor suppression [6,157,158,181]. Furthermore, it has also been re-
ported that otherMMPs, includingMMP-3 [182],MMP-9 [183],MMP-11
[184] or MMP-19 [185,186] play dual roles as pro- or anti-tumorigenic
enzymes depending on tissue type and stage of the disease (Table 2).
Likewise, gain- or loss-of-function mouse models have allowed the
identiﬁcation of some of the in vivo substrates for these enzymes. This is
another step forward in the complex relationship between MMPs and
cancer, since many non-matrix bioactive molecules, such as growth
factor receptors, chemokines, cytokines, apoptotic ligands or angiogenic
factors, have been identiﬁed as substrates for MMPs [37]. Altogether,
these ﬁndings illustrate the diversity of MMP functions associated with
cancer and provide explanations for the disappointing results of the ﬁrst
clinical trials based on the use of broad spectrum MMP inhibitors [72].
The increasing complexity of the in vivo functions of MMPs also
affects many other pathological contexts, particularly those involving
inﬂammatory conditions where MMP expression is frequently dere-
gulated [5]. In this sense, genetically modiﬁed mice have been essential
to demonstrate the relevance of these enzymes in prevalent human
pathologies, such as rheumatic, pulmonary, cardiovascular and neuro-
degenerative disorders. Remarkably, these studies have also shown
opposing and unexpected effects among differentmembers of theMMP
family on the progression of these diseases (Table 2). Thus, and
somewhat surprisingly, mice deﬁcient inMmp2 orMmp3 develop more
severe arthritis than control animals [187,188]. Likewise, deﬁciency in
Mmp3 or Mmp13 results in more stable atherosclerotic plaques
[189,190]. By contrast, deletion ofMmp2 orMmp9 reduces the formation
of the plaques and attenuates cardiac ﬁbrosis after experimental
myocardial infarction [191,192]. In neuroinﬂammatory diseases, such
as experimental autoimmune encephalomyelitis (EAE), the murine
model of multiple sclerosis, MMPs also show opposite roles. Indeed,
certain mouse MMPs, including Mmp-2, Mmp-7, Mmp-8 and Mmp-9
[193–195], contribute to the severity of the clinical symptoms of
paralysis whereas others, such as Mmp-12 [196], play protective func-
tions. Similarly, the role of MMPs in respiratory disorders is very
complex, since it is not clear yet whetherMMPs upregulation is harmful
in acute and chronic lung pathologies. Genetically modiﬁed mice
have demonstrated that lack of Mmp2, Mmp8 or both Mmp2/Mmp9[197–199] increases the allergic response in a mouse model of asthma
due to the failure in clearing inﬂammatory cells. In this sense, mice
deﬁcient in Mmp10 also show more severe pulmonary inﬂammation
and greater susceptibility to death followingbacterial infection [200]. By
contrast, deletion of Mmp7 or Mmp12 [201,202] resulted beneﬁcial in
chronic lung diseases, such as pulmonary ﬁbrosis or emphysema.
Overall, the generation of gain- or loss-of-function mouse models
has been essential to demonstrate the complex and even paradoxical
roles thatMMPsplay inphysiological andpathological processes [203].
Likewise, these approaches have allowed the in vivo validation and
identiﬁcation of speciﬁc substrates, providing a better understanding
of the mechanisms involved in the development of the diseases.
Therefore, it is necessary to continue analyzing and generating the
remaining MMP knock-outs, but also to improve the experimental
approaches through the creation of new biological models with the
crossing ofMmp-targetedmice and transgenic animals overexpressing
oncogenes that mimic human malignancies. Nevertheless, it is impor-
tant to emphasize that a constitutive deletion of a gene may not have
the same effect as inhibiting the enzyme in a speciﬁc spatiotemporal
context during the adult life. Thus, additional in vivo strategies able to
modulate MMPs activity, such as conditional targeting or RNA inter-
ference delivery, will be required in order to improve the extrapolation
of mice experimentation to therapeutic advances in human diseases.
10. Conclusions and perspectives
The availability of the complete genome sequences of different
organisms has recently allowed the identiﬁcation of their entire pro-
tease complements including that of MMPs, and the establishment of
novel insights into their evolutionary diversiﬁcation in all kingdoms of
life. The family portrait of this group of metalloproteinases has
revealed that, beyond an archetypal design, they exhibit a structural
diversity which allows them to participate in multiple biological and
pathological functions. Over the last years, there has been a substantial
change in our view of these MMP functions. Thus, the initial concept
that MMPs were mainly implicated in the demolition of the structural
groundwork that supports cells and generates tissue barriers has been
replaced by a new vision of these enzymes as signaling scissors con-
trolling multiple processes. The generation of animal models of gain-
or loss-of-function for MMPs has been crucial for the identiﬁcation of
some novel and unexpected functions of these metalloproteinases.
Likewise, these models have been very useful for the identiﬁcation of
in vivo substrates of MMPs and for the establishment of causal
relationships between dysregulation of these enzymes and develop-
ment of different human diseases. Nevertheless, the generation of new
animal models is still necessary to evaluate the function of several
MMP family members such as MMP-23, MMP-27 or MT6-MMP which
are largely uncharacterized yet. Some of these newmodelswill require
the generation of double or even triple knock-out models to minimize
the putative occurrence of functional redundancy or compensatory
mechanisms between members of the MMP family. The generation of
conditional mouse models to better understand the role of some
enzymes, and especially MT1-MMP, in the diverse conditions inwhich
they are presumably involved is also urgent. These genetic approaches
to MMP function will also need to be complemented with strategies
derived from the application of RNA interferencemethods to theMMP
ﬁeld. Genomic studies coupled to functional analysis of promoter re-
gions of MMP genes have already provided important information
about themolecularmechanisms controlling their expression in health
and disease. Nevertheless, it will be necessary to complete these
regulatory studies onMMPs and extend them to other levels of control
including those based on epigenetic or miRNA-mediatedmechanisms,
which have acquired a great relevance in many eukaryotic genes but
whose inﬂuence on the MMP gene family is still largely unknown.
Likewise, and despite the recent progress in the identiﬁcation of
MMPmutations and polymorphisms associated with different genetic
15M. Fanjul-Fernández et al. / Biochimica et Biophysica Acta 1803 (2010) 3–19diseases, further functional analysis will be necessary to clarify the
relevance of these alterations in the context of themultiple genetic and
epigenetic changes detected in complex diseases such as cancer.
Hopefully, all these studies will provide new insights into the multiple
questions still open in relation to a family of enzymes which had a
modest irruption into the protease scene owing to their implication in
tail resorption of tadpoles, and noware considered essentialmediators
of multiple events in all living organisms.
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